The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits

Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

(2013) Alison R Meloni et al.   Cardiovascular Diabetology

The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective

(2013) Manfredi Rizzo et al.   Clinical Lipidology

Incretin Therapy and Islet Pathology: A Time for Caution

(2013) S. E. Kahn   DIABETES

Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(2013) A. E. Butler et al.   DIABETES

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

(2013) M. A. Nauck   DIABETES CARE

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 therapies safe?

(2013) P. C. Butler et al.   DIABETES CARE

Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies

(2013) Paulus Wohlfart et al.   Journal of Translational Medicine

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secrecy does not serve us well

(2013) F. Godlee   BMJ-British Medical Journal

Cardiovascular benefits of incretins

(2013) A. H. Barnett et al.   BMJ-British Medical Journal

Incretin therapy: should adverse consequences have been anticipated?

(2013) E. Gale   BMJ-British Medical Journal

Helping patients make sense of the risks of taking GLP-1 agonists

(2013) V. M. Montori   BMJ-British Medical Journal

Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds

(2013) D. Cohen   BMJ-British Medical Journal

GLP-1 based agents and acute pancreatitis

(2013) E. A. M. Gale   BMJ-British Medical Journal

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

(2013) D. Cohen   BMJ-British Medical Journal

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

(2013) D. T. Eurich et al.   BMJ-British Medical Journal

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis

(2012) W. Rathmann et al.   DIABETES OBESITY & METABOLISM

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

(2012) M. Wenten et al.   DIABETIC MEDICINE

Potential cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: current evidence and ongoing trials

(2012) O. Mosenzon et al.   EUROPEAN HEART JOURNAL SUPPLEMENTS

Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates

(2012) R. P. Shannon et al.   EUROPEAN HEART JOURNAL SUPPLEMENTS

The design and rationale of the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus–Thrombolysis in Myocardial Infarction (SAVOR-TIMI) 53 Study

(2011) Benjamin M. Scirica et al.   AMERICAN HEART JOURNAL

EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)

(2011) William B. White et al.   AMERICAN HEART JOURNAL

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

(2011) Robert Ratner et al.   Cardiovascular Diabetology

Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

(2011) Steven P Marso et al.   Diabetes & Vascular Disease Research

A cohort study of acute pancreatitis in relation to exenatide use

(2011) D. D. Dore et al.   DIABETES OBESITY & METABOLISM

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Effects of DPP-4 inhibition on cardiac metabolism and function in mice

(2011) M. Lenski et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Heart Disease and Stroke Statistics—2011 Update

(2010) Véronique L. Roger et al.   CIRCULATION

Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

(2010) M. C. Bunck et al.   DIABETES CARE

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Epidemiology of Gallstones

(2010) Laura M. Stinton et al.   GASTROENTEROLOGY CLINICS OF NORTH AMERICA

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis

(2010) S. S. Engel et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Liraglutide: effects beyond glycaemic control in diabetes treatment

(2010) J. B. McGill   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis

(2010) Deepak L. Bhatt et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

(2010) Deepson S Shyangdan et al.   BMC Endocrine Disorders

Trends in All-Cause and Cardiovascular Disease Mortality Among Women and Men With and Without Diabetes Mellitus in the Framingham Heart Study, 1950 to 2005

(2009) Sarah Rosner Preis et al.   CIRCULATION

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes: Interactions With Metformin

(2009) A. V. Matveyenko et al.   DIABETES

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

(2008) David C. Klonoff et al.   CURRENT MEDICAL RESEARCH AND OPINION